Benitec Biopharma

Benitec Biopharma Inc. is a development-stage biotechnology company focused on the advancement of novel genetic medicines. The company's proprietary platform, called DNA-directed RNA interference or ddRNAi, combines RNA interference (RNAi) with gene therapy to create drugs that enable the long-term silencing of disease-causing genes following a single administration. The company is developing ddRNAi-based therapies for the treatment of chronic and life-threatening human diseases, including Oculopharyngeal Muscular Dystrophy (OPMD) and chronic hepatitis B.